NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Phibro Animal Health Corporation PAHC
14 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$1.3B
▲ 27.4% vs FY2023
EPS · FY24
—
Dividend / sh · FY24
$0.48
Payout · FY24
40%
ROE · FY24
17.8%
Net margin · FY24
3.7%
Dividend coverage
2.5×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.3B
Revenue, FY2024 · full 14-year series below
Revenue
Net income
4 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2024
EPS
Dividend
Earnings covered the dividend 2.5 times — the rest stayed in the company.
Profitability
17.8%
Return on equity, FY2024
ROE
Operating margin8.5%
Net margin3.7%
Return on assets4.1%
Each USD of equity produced 18 cents of profit this year.
Returned to shareholders
USD 19.4M
returned in FY2024 · dividends + net buybacks
Dividends paidUSD 19.4M
Net buybacks—
Share of profit40.3%
Consecutive raises—
USD 19.4M in dividends — 40% of the year's profit went back to shareholders.
Growth
+10.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+11.2%
+10.1%
+5.6%
Net income
−0.6%
+7.5%
−2.2%
EPS, diluted
−0.6%
+7.5%
−2.4%
Dividend / share
+0.0%
+0.0%
+1.8%
Returned to shareholders
+0.0%
+0.0%
+2.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.4B
total assets, end of FY2024
Total assetsUSD 1.4B
EquityUSD 285.7M
CashUSD 68.0M
Current ratio2.76×
Equity funds 21% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
1.3
1.0
1.0
0.9
0.8
0.8
0.8
0.8
0.8
0.8
0.7
0.7
0.7
0.7
Operating income $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
EBITDA $B
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
Net income $B
0.0
0.0
0.0
0.0
0.1
0.0
0.1
0.1
0.1
0.1
0.1
−0.0
0.0
0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
0.48
0.48
0.48
0.48
0.48
0.48
0.46
0.40
0.40
0.40
0.40
0.82
0.10
·
Payout %
40
805
60
40
36
58
34
25
24
19
26
−799
12
·
ROE %
17.8
0.9
12.0
19.6
25.5
16.6
27.3
38.6
53.5
137.8
269.2
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
54 of 54
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed